- Home
- AIMD vs POAI Comparison
AIMD vs POAI Comparison
Compare AIMD & POAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIMD
- POAI
- Stock Information
- Founded
- AIMD 1984
- POAI 2002
- Country
- AIMD United States
- POAI United States
- Employees
- AIMD N/A
- POAI N/A
- Industry
- AIMD Biotechnology: Pharmaceutical Preparations
- POAI Industrial Specialties
- Sector
- AIMD Health Care
- POAI Health Care
- Exchange
- AIMD Nasdaq
- POAI Nasdaq
- Market Cap
- AIMD 8.2M
- POAI 8.9M
- IPO Year
- AIMD N/A
- POAI N/A
- Fundamental
- Price
- AIMD $0.54
- POAI $1.10
- Analyst Decision
- AIMD
- POAI Hold
- Analyst Count
- AIMD 0
- POAI 1
- Target Price
- AIMD N/A
- POAI N/A
- AVG Volume (30 Days)
- AIMD 168.9K
- POAI 82.2K
- Earning Date
- AIMD 05-12-2025
- POAI 05-15-2025
- Dividend Yield
- AIMD N/A
- POAI N/A
- EPS Growth
- AIMD N/A
- POAI N/A
- EPS
- AIMD N/A
- POAI N/A
- Revenue
- AIMD $20,729.00
- POAI $1,623,817.00
- Revenue This Year
- AIMD N/A
- POAI $486.27
- Revenue Next Year
- AIMD N/A
- POAI $65.50
- P/E Ratio
- AIMD N/A
- POAI N/A
- Revenue Growth
- AIMD N/A
- POAI N/A
- 52 Week Low
- AIMD $0.40
- POAI $0.55
- 52 Week High
- AIMD $1.46
- POAI $3.06
- Technical
- Relative Strength Index (RSI)
- AIMD 50.95
- POAI 50.57
- Support Level
- AIMD $0.51
- POAI $0.85
- Resistance Level
- AIMD $0.57
- POAI $1.19
- Average True Range (ATR)
- AIMD 0.04
- POAI 0.09
- MACD
- AIMD -0.00
- POAI 0.01
- Stochastic Oscillator
- AIMD 36.71
- POAI 42.74
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.
About POAI Predictive Oncology Inc.
Predictive Oncology Inc functions in the healthcare domain. The firm's reportable segments are Pittsburgh segment that provides services which include the application of AI using its proprietary biobank of 150,000+ tumor samples. It also creates proprietary 3D culture models used in drug development; Birmingham segment that provides contract services and research focused on solubility improvements, stability studies, and protein production; and Eagan segment that produces the FDA-cleared STREAMWAY System and associated products for automated medical fluid waste management and patient-to-drain medical fluid disposal. It derives maximum revenue from Eagan Segment.